Auris Medical Holding Ltd.

3.50-0.0200-0.57%Vol 934.90K1Y Perf 329.73%
Apr 16th, 2021 16:00 DELAYED
BID3.49 ASK3.54
Open3.55 Previous Close3.52
Pre-Market- After-Market3.57
 - -  0.07 2.00%
Target Price
2.50 
Analyst Rating
— 0.00
Potential %
-28.57 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★ —    52.51
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap39.96M 
Earnings Rating
Neutral
Price Range Ratio 52W %
47.19 
Earnings Date
31st Mar 2021

Today's Price Range

3.323.59

52W Range

0.73006.60

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-18.79%
1 Month
-15.46%
3 Months
32.58%
6 Months
256.89%
1 Year
329.73%
3 Years
-87.04%
5 Years
-99.59%
10 Years
-

TickerPriceChg.Chg.%
EARS3.50-0.0200-0.57
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
3.70
3.80
0.01
0.03
-59.80
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
-
-3 106.60
-3 102.20
-
-
RevenueValueIndustryS&P 500US Markets
197.59K
0.03
-
-
Earnings HistoryEstimateReportedSurprise %
Q04 2018--2.40-
Q03 2018--2.80-
Q02 2018--10.20-
Q01 2018--6.40-
Q04 2017--20.20-
Q03 2017-2.00-1.5025.00
Q02 2017-2.10-1.2042.86
Q01 2017-0.10-0.22-120.00
Earnings Per EndEstimateRevision %Trend
9/2017 QR-0.200.00-
12/2017 QR-0.140.00-
12/2020 FY-1.0060.78Positive
12/2021 FY-2.1546.25Positive
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume934.90K
Shares Outstanding11.42M
Trades Count3.74K
Dollar Volume1.48M
Avg. Volume4.40M
Avg. Weekly Volume13.89M
Avg. Monthly Volume7.27M
Avg. Quarterly Volume5.01M

Auris Medical Holding Ltd. (NASDAQ: EARS) stock closed at 3.5 per share at the end of the most recent trading day (a -0.57% change compared to the prior day closing price) with a volume of 937.58K shares and market capitalization of 39.96M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 12 people. Auris Medical Holding Ltd. CEO is Thomas Meyer.

The one-year performance of Auris Medical Holding Ltd. stock is 329.73%, while year-to-date (YTD) performance is 33.59%. EARS stock has a five-year performance of -99.59%. Its 52-week range is between 0.73 and 6.6, which gives EARS stock a 52-week price range ratio of 47.19%

Auris Medical Holding Ltd. currently has a PE ratio of 5.90, a price-to-book (PB) ratio of 0.37, a price-to-sale (PS) ratio of 154.28, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -54.75%, a ROC of -83.98% and a ROE of -72.06%. The company’s profit margin is -%, its EBITDA margin is -3 102.20%, and its revenue ttm is $197.59 Thousand , which makes it $0.03 revenue per share.

Of the last four earnings reports from Auris Medical Holding Ltd., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Auris Medical Holding Ltd.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Auris Medical Holding Ltd. is (0), with a target price of $2.5, which is -28.57% compared to the current price. The earnings rating for Auris Medical Holding Ltd. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Auris Medical Holding Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Auris Medical Holding Ltd. has a Neutral technical analysis rating based on Technical Indicators (ADX : 32.76, ATR14 : 0.71, CCI20 : -35.66, Chaikin Money Flow : -0.22, MACD : 0.14, Money Flow Index : 89.29, ROC : 8.36, RSI : 57.63, STOCH (14,3) : 21.69, STOCH RSI : 0.30, UO : 42.89, Williams %R : -78.31), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Auris Medical Holding Ltd. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
1 (100.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
0 (0.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Summary Rating--Strong Buy
1.00

Auris Medical Holding Ltd.

Auris Medical Holding Ltd is a clinical-stage biopharmaceutical company. The company develops novel products for the treatment of inner ear disorders. It has two projects in advanced clinical development Keyzilen for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. It is developing Keyzilen for the treatment of acute inner ear (peripheral) tinnitus following traumatic cochlear injury or otitis media (middle ear infection). Keyzilen contains Esketamine hydrochloride, an N-Methyl-D-Aspartate (NMDA) receptor antagonist, formulated in a biocompatible and fully biodegradable gel. It is also developing AM-111 for the treatment of acute inner ear (sensorineural) hearing loss (ASNHL).

CEO: Thomas Meyer

Telephone: +1441 2955950

Address: 2 Church Street, Hamilton HM11, , BM

Number of employees: 12

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

48%52%

Bearish Bullish

53%47%

News

Stocktwits